Full name
ZAKŁAD BADAWCZO-WDROŻENIOWY OŚRODKA SALMONELLA "IMMUNOLAB" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
46.46.Z - Wholesale of pharmaceutical goods
46.90.Z - Non-specialised wholesale trade
47.73.Z - Dispensing chemist in specialised stores
47.74.Z - Retail sale of medical and orthopaedic goods in specialised stores
72.19.Z - Other research and experimental development on natural sciences and engineering
85.59.B - Other out-of-school forms of education, not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | -2,4 | -2,6 | -2,6 | 0,1 |
Gross profit (loss) | -0,1 | 1 | 0,1 | -89,7 |
EBITDA | 0,5 | 1,4 | 0,3 | -75,4 |
Short time liabilities | 0,6 | 0,3 | 0,1 | -65,2 |
Other operating costs | 0,7 | 0 | 1 | 2 080 124,2 |
Equity capital | 0,5 | 1,4 | 1,6 | 10,4 |
Operating profit (EBIT) | -0 | 1,1 | 0,2 | -84,5 |
Assets | 2,6 | 2,8 | 2,4 | -13,9 |
Net profit (loss) | -0,1 | 1 | 0,1 | -90,5 |
Cash | 1,1 | 0,7 | 0,1 | -80,8 |
Liabilities and provisions for liabilities | 2,2 | 1,3 | 0,8 | -40 |
Net income from sale | 1,2 | 1,4 | 2,1 | 52 |
Working assets | 1,3 | 0,9 | 0,7 | -26,7 |
Other income costs | 3,1 | 3,7 | 3,7 | 0,5 |
Depreciation | 0,5 | 0,3 | 0,2 | -39,7 |
% | % | % | p.p. | |
Profitability of capital | -20,9 | 67,9 | 5,9 | -62 |
Equity capital to total assets | 17,2 | 51,8 | 66,4 | 14,6 |
Gross profit margin | -8,1 | 73,3 | 5 | -68,3 |
EBITDA Margin | 42,1 | 103,3 | 16,7 | -86,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 173 | 83 | 19 | -64 |
Current financial liquidity indicator | 2.3682539463043213 | 2.9052746295928955 | 6.110328197479248 | 3,2 |
Net dept to EBITDA | -0.18928752839565277 | -0.1849757879972458 | 0.9251986145973206 | 1,1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane